CryoCath
This article was originally published in The Gray Sheet
Executive Summary
Company reps meet with FDA June 4 to discuss a trial design for the Artic Circler atrial fibrillation ablation catheter; firm hopes to begin an IDE trial later this year. The meeting came two days after FDA's Circulatory System Devices Panel unanimously voted against recommending approval of Cardima's Revelation Tx AF ablation catheter, largely due to difficulties in obtaining AF burden data from patients (1"The Gray Sheet" June 2, 2003, p. 3)...
You may also be interested in...
Cardima’s Revelation: AF Self-Monitoring, Hazy Endpoints Hamper Review
The ability of self-reporting to accurately track reduction in atrial fibrillation burden is cast into doubt by FDA panel experience with Cardima's Revelation ablation system data submission
Prestige Expands UK Eye Care Range In Response To Consumer Demand
A “great consumer response” to TheraTears in the UK leads Prestige Consumer Healthcare to add TheraTears 5-in-1 Irritation and Redness eye drops to the range.
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.